Orserdu (elacestrant tablets – Stemline/Menarini) — Cigna
Breast cancer in postmenopausal women or men – estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 gene (ESR1)-mutated advanced or metastatic disease
Initial criteria
- Patient age ≥ 18 years; AND
- Patient has recurrent or metastatic disease; AND
- Patient has estrogen receptor positive (ER+) disease; AND
- Patient has human epidermal growth factor receptor 2 (HER2)-negative disease; AND
- Patient has estrogen receptor 1 gene (ESR1)-mutated disease; AND
- Patient has tried at least one endocrine therapy (e.g., fulvestrant, anastrozole, exemestane, letrozole, tamoxifen)
Approval duration
1 year